

Jermaine D Jones

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9324607/publications.pdf>

Version: 2024-02-01

59
papers

2,045
citations

304743

22
h-index

243625

44
g-index

59
all docs

59
docs citations

59
times ranked

2552
citing authors

#	ARTICLE	IF	CITATIONS
1	Polydrug abuse: A review of opioid and benzodiazepine combination use. <i>Drug and Alcohol Dependence</i> , 2012, 125, 8-18.	3.2	565
2	Risks, Management, and Monitoring of Combination Opioid, Benzodiazepines, and/or Alcohol Use. <i>Postgraduate Medicine</i> , 2013, 125, 115-130.	2.0	179
3	The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers. <i>Addiction Biology</i> , 2016, 21, 895-903.	2.6	85
4	Glial and neuroinflammatory targets for treating substance use disorders. <i>Drug and Alcohol Dependence</i> , 2017, 180, 156-170.	3.2	79
5	The Pharmacogenetics of Alcohol Use Disorder. <i>Alcoholism: Clinical and Experimental Research</i> , 2015, 39, 391-402.	2.4	71
6	Effects of Ibudilast on the Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Recently Detoxified Adults with Opioid Dependence. <i>Neuropsychopharmacology</i> , 2017, 42, 1825-1832.	5.4	59
7	Effect of Buprenorphine Weekly Depot (CAM2038) and Hydromorphone Blockade in Individuals With Opioid Use Disorder. <i>JAMA Psychiatry</i> , 2017, 74, 894.	11.0	58
8	Effects of Acute Oral Naltrexone on the Subjective and Physiological Effects of Oral D-Amphetamine and Smoked Cocaine in Cocaine Abusers. <i>Neuropsychopharmacology</i> , 2013, 38, 2427-2438.	5.4	49
9	No evidence of compensatory drug use risk behavior among heroin users after receiving take-home naloxone. <i>Addictive Behaviors</i> , 2017, 71, 104-106.	3.0	49
10	Brief overdose education can significantly increase accurate recognition of opioid overdose among heroin users. <i>International Journal of Drug Policy</i> , 2014, 25, 166-170.	3.3	46
11	Sex Differences Among Opioid-Abusing Patients With Chronic Pain in a Clinical Trial. <i>Journal of Addiction Medicine</i> , 2015, 9, 46-52.	2.6	46
12	A review of human drug self-administration procedures. <i>Behavioural Pharmacology</i> , 2013, 24, 384-395.	1.7	44
13	Glial modulators: a novel pharmacological approach to altering the behavioral effects of abused substances. <i>Expert Opinion on Investigational Drugs</i> , 2012, 21, 169-178.	4.1	42
14	Assessment of a formulation designed to be crush-resistant in prescription opioid abusers. <i>Drug and Alcohol Dependence</i> , 2012, 126, 206-215.	3.2	42
15	A comparison among tapentadol tamper-resistant formulations (TRF) and oxycodone/extended-release naltrexone (non-TRF) in prescription opioid abusers. <i>Addiction</i> , 2013, 108, 1095-1106.	3.3	38
16	How competent are people who use opioids at responding to overdoses? Qualitative analyses of actions and decisions taken during overdose emergencies. <i>Addiction</i> , 2019, 114, 708-718.	3.3	38
17	A review of pharmacogenetic studies of substance-related disorders. <i>Drug and Alcohol Dependence</i> , 2015, 152, 1-14.	3.2	29
18	Abuse potential of intranasal buprenorphine versus buprenorphine/naloxone in buprenorphine-maintained heroin users. <i>Addiction Biology</i> , 2015, 20, 784-798.	2.6	28

#	ARTICLE	IF	CITATIONS
19	The Increasing Prevalence of Fentanyl: A Urinalysis-Based Study Among Individuals With Opioid Use Disorder in New York City. <i>American Journal on Addictions</i> , 2021, 30, 65-71.	1.4	26
20	The Subjective, Reinforcing, and Analgesic Effects of Oxycodone in Patients with Chronic, Non-Malignant Pain who are Maintained on Sublingual Buprenorphine/Naloxone. <i>Neuropsychopharmacology</i> , 2011, 36, 411-422.	5.4	25
21	Comparison of a drug versus money and drug versus drug self-administration choice procedure with oxycodone and morphine in opioid addicts. <i>Behavioural Pharmacology</i> , 2013, 24, 504-516.	1.7	25
22	Pioglitazone, a PPAR β agonist, reduces nicotine craving in humans, with marginal effects on abuse potential. <i>Pharmacology Biochemistry and Behavior</i> , 2017, 163, 90-100.	2.9	24
23	Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2020, 208, 107859.	3.2	24
24	Oxycodone Abuse in New York City: Characteristics of Intravenous and Intranasal Users. <i>American Journal on Addictions</i> , 2011, 20, 190-195.	1.4	23
25	Differential involvement of the norepinephrine, serotonin and dopamine reuptake transporter proteins in cocaine-induced taste aversion. <i>Pharmacology Biochemistry and Behavior</i> , 2009, 93, 75-81.	2.9	22
26	Dopamine, norepinephrine and serotonin transporter gene deletions differentially alter cocaine-induced taste aversion. <i>Pharmacology Biochemistry and Behavior</i> , 2010, 94, 580-587.	2.9	22
27	Chronic pain and opioid abuse: Factors associated with health-related quality of life. <i>American Journal on Addictions</i> , 2017, 26, 815-821.	1.4	21
28	Strain-dependent sex differences in the effects of alcohol on cocaine-induced taste aversions. <i>Pharmacology Biochemistry and Behavior</i> , 2006, 83, 554-560.	2.9	20
29	The effects of pioglitazone, a PPAR β receptor agonist, on the abuse liability of oxycodone among nondependent opioid users. <i>Physiology and Behavior</i> , 2016, 159, 33-39.	2.1	18
30	Searching for evidence of genetic mediation of opioid withdrawal by opioid receptor gene polymorphisms. <i>American Journal on Addictions</i> , 2016, 25, 41-48.	1.4	17
31	The effects of heroin administration and drug cues on impulsivity. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2016, 38, 709-720.	1.3	16
32	Abuse liability of intravenous buprenorphine vs. buprenorphine/naloxone: Importance of absolute naloxone amount. <i>Drug and Alcohol Dependence</i> , 2017, 179, 362-369.	3.2	15
33	The PPAR β Agonist Pioglitazone Fails to Alter the Abuse Potential of Heroin, But Does Reduce Heroin Craving and Anxiety. <i>Journal of Psychoactive Drugs</i> , 2018, 50, 390-401.	1.7	15
34	A randomized, double-blind, placebo-controlled study of the kappa opioid receptor antagonist, CERCâ€501, in a human laboratory model of smoking behavior. <i>Addiction Biology</i> , 2020, 25, e12799.	2.6	15
35	Opioid overdose reversals using naloxone in New York City by people who use opioids: Implications for public health and overdose harm reduction approaches from a qualitative study. <i>International Journal of Drug Policy</i> , 2020, 79, 102751.	3.3	15
36	Opioid-Like Effects of the Neurokinin 1 Antagonist Aprepitant in Patients Maintained on and Briefly Withdrawn from Methadone. <i>American Journal of Drug and Alcohol Abuse</i> , 2013, 39, 86-91.	2.1	13

#	ARTICLE	IF	CITATIONS
37	The effects of cocaine, alcohol and cocaine/alcohol combinations in conditioned taste aversion learning. <i>Pharmacology Biochemistry and Behavior</i> , 2005, 82, 207-214.	2.9	11
38	The reinforcing and subjective effects of intravenous and intranasal buprenorphine in heroin users. <i>Pharmacology Biochemistry and Behavior</i> , 2014, 122, 299-306.	2.9	11
39	Factor structure and psychometric properties of the Connorâ€œDavidson resilience scale (CD-RISC) in individuals with opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2021, 221, 108632.	3.2	11
40	Need and utility of a polyethylene glycol marker to ensure against urine falsification among heroin users. <i>Drug and Alcohol Dependence</i> , 2015, 153, 201-206.	3.2	10
41	Can Naloxone Be Used to Treat Synthetic Cannabinoid Overdose?. <i>Biological Psychiatry</i> , 2017, 81, e51-e52.	1.3	10
42	Factors associated with withdrawal symptoms and anger among people resuscitated from an opioid overdose by take-home naloxone: Exploratory mixed methods analysis. <i>Journal of Substance Abuse Treatment</i> , 2020, 117, 108099.	2.8	10
43	Assessing the contribution of opioid- and dopamine-related genetic polymorphisms to the abuse liability of oxycodone. <i>Pharmacology Biochemistry and Behavior</i> , 2019, 186, 172778.	2.9	9
44	Potential of Glial Cell Modulators in the Management of Substance Use Disorders. <i>CNS Drugs</i> , 2020, 34, 697-722.	5.9	9
45	Improving Translational Research Outcomes for Opioid Use Disorder Treatments. <i>Current Addiction Reports</i> , 2021, 8, 109-121.	3.4	9
46	Intervention in an opioid overdose event increases interest in treatment among individuals with opioid use disorder. <i>Substance Abuse</i> , 2020, 42, 1-5.	2.3	8
47	Racial Differences in HIV and HCV Risk Behaviors, Transmission, and Prevention Knowledge among Non-Treatment-Seeking Individuals with Opioid Use Disorder. <i>Journal of Psychoactive Drugs</i> , 2017, 49, 59-68.	1.7	6
48	Changes in cardiac vagal tone as measured by heart rate variability during naloxone-induced opioid withdrawal. <i>Drug and Alcohol Dependence</i> , 2019, 204, 107538.	3.2	6
49	Behavioral effects and drug vulnerability in rats exposed to Pfiesteria toxin. <i>Neurotoxicology and Teratology</i> , 2005, 27, 701-710.	2.4	5
50	A qualitative study of repeat naloxone administrations during opioid overdose intervention by people who use opioids in New York City.. <i>International Journal of Drug Policy</i> , 2021, 87, 102968.	3.3	5
51	A randomized clinical trial of the effects of brief versus extended opioid overdose education on naloxone utilization outcomes by individuals with opioid use disorder. <i>Drug and Alcohol Dependence</i> , 2022, 237, 109505.	3.2	5
52	Impact of inâ€œpatient research participation on subsequent heroin use patterns: implications for ethics and public health. <i>Addiction</i> , 2012, 107, 642-649.	3.3	4
53	Relative potency of intravenous oxymorphone compared to other μ opioid agonists in humans â€œ pilot study outcomes. <i>Psychopharmacology</i> , 2021, 238, 2503-2514.	3.1	4
54	Naloxoneâ€œInduced Withdrawal in Individuals With and Without Fentanylâ€œPositive Urine Samples. <i>American Journal on Addictions</i> , 2020, 29, 51-56.	1.4	2

#	ARTICLE	IF	CITATIONS
55	The acute and repeated effects of cigarette smoking and smoking-related cues on impulsivity. <i>Drug and Alcohol Review</i> , 2020, 40, 864-868.	2.1	2
56	Emotional Reactions of Trained Overdose Responders who use Opioids following Intervention in an Overdose Event. <i>Substance Abuse</i> , 2022, 43, 581-591.	2.3	2
57	The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward/punishment sensitivity and methamphetamine's effects. <i>Behavioural Pharmacology</i> , 2022, Publish Ahead of Print, .	1.7	2
58	Multi-informant Implementation and Intervention Outcomes of Opioid Overdose Education and Naloxone Distribution in New York City. <i>Global Implementation Research and Applications</i> , 2021, 1, 209-222.	1.1	1
59	Understanding preferences for type of take-home naloxone device: international qualitative analysis of the views of people who use opioids. <i>Drugs: Education, Prevention and Policy</i> , 0, , 1-12.	1.3	0